Prostate Cancer

Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Oliver Sartor from Tulane Cancer Center Discusses the Novel Agent Radium-223

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.

Two trials are underway that not only address bone-related issues but might improve survival rates for patients.

Vitamin E may increase the risk of developing prostate cancer in men who have taken the supplement for 5 years or longer.

Dendreon estimates that only about 25% of eligible prescribing physicians were aware that Medicare had decided to cover Provenge for its on-label use of treating prostate cancer.

Investigational drug that emits alpha radiation shows significant improvement in overall survival.

Two studies enhance understanding of risk factors for prostate cancer.

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasis–free survival with Xgeva versus placebo.

New findings suggest that long-term, regular acetaminophen use may be associated with a lower risk of prostate cancer.

Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Donna Berry on the Challenges Patients With Prostate Cancer Face

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

A search for potential chemopreventive agents for prostate cancer uncovered an unlikely candidate in digoxin, one of the oldest drugs for cardiovascular disorders

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized, high-risk prostate cancer patients

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.

Screening for prostate cancer does work, despite controversy about its efficacy

Therapies that target bone metastases have been developed for more than a decade.

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer